Azenta, Inc. ( (AZTA) ) has released its Q1 earnings. Here is a breakdown of the information Azenta, Inc. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Azenta, Inc., a global leader in life sciences solutions, provides comprehensive sample management and multiomics services to facilitate advancements in drug development and clinical research across pharmaceutical, biotech, academic, and healthcare institutions worldwide.
In its first-quarter results for fiscal 2025, Azenta, Inc. reported a 4% increase in revenue from continuing operations, totaling $148 million, with significant contributions from its Sample Management Solutions and Multiomics services. The company also highlighted a strong free cash flow and improvements in both gross and operating margins.
Key financial metrics showed that while organic revenue grew by 4%, the company faced an operating loss of $11 million due to increased operating expenses, primarily in selling, general, and administrative costs. Nevertheless, Azenta achieved an adjusted EBITDA of $13 million, reflecting an 89% year-over-year improvement, and maintained a robust cash position of $530 million.
The revenue from Sample Management Solutions rose by 3% year-over-year, driven by higher sales in consumables and clinical store systems, while Multiomics saw a 6% increase, led by growth in next-generation sequencing. Despite a loss per share, the company maintained its non-GAAP diluted EPS at $0.08, consistent with the previous year.
Looking ahead, Azenta reiterates its revenue guidance for the full fiscal year 2025, projecting organic revenue growth between 3% to 5% and an expansion in adjusted EBITDA margin by approximately 300 basis points, reflecting confidence in its strategic initiatives and market positioning despite current challenges.
